Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells Glioblastoma (GBM) is an aggressive tumor of the brain, with an average post-diagnosis survival of 15 months. GBM stem cells (GBMSC) resist the standard-of-care therapy, temozolomide, and are consider...

pmc.ncbi.nlm.nih.gov/articles/PMC...

"Previously, we identified four piperazine compounds ( #cinnarizine, #hydroxyzine, #meclizine, and #flunarizine) as novel mTORC1 specific inhibitors."